Definitive Contract HHSN272201600029C
Award Date
9/19/16
Potential Completion Date
3/31/26
Potential Value
$49M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Venatorx Pharmaceuticals Inc.
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Malvern, PA 19355, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
13
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $44,247,749 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Venatorx Pharmaceuticals Inc. (doing business as Venatorx) for the development of a novel beta-lactamase inhibitor targeting multidrug-resistant Acinetobacter baumannii. This contract is not set aside and was awarded through full and open competition. Venatorx is a biopharmaceutical company...
This is a $167,067,962 definitive cost-sharing contract awarded to Venatorx Pharmaceuticals Inc. by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR). The contract, which does not have a set-aside designation, supports the advanced research and development of new antibiotics to treat drug-resistant gram-negative bacteria, including public health pathogens. This work aligns with BARDA's mission to develop medical countermeasures...
The U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $318,625,321.00 cost-plus-fixed-fee contract to Venatorx Pharmaceuticals Inc. for the development of an antibiotic to treat infections caused by biothreat pathogens such as Yersinia pestis, Francilla tularensis, and Burkholderia pseudomallei. This contract, which has a period of performance through September 2032, was not set aside for any particular business...
This is a federal contract award made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services (HHS), to Venatorx Pharmaceuticals Inc., a biopharmaceutical company specializing in the discovery and development of novel anti-infective therapeutics. The contract, valued at $147,481,537.00, does not have a set-aside designation and was awarded as a definitive, cost-sharing contract. The work under this contract focuses...
The Defense Threat Reduction Agency awarded a $19,969,099.47 cost-plus-fixed-fee definitive contract to Venatorx Pharmaceuticals Inc. (doing business as Venatorx) for the research, development, and manufacturing of penicillin binding proteins. The contract does not have a set-aside designation and has a completion date of October 27, 2023. Venatorx, a for-profit organization, has a history of receiving federal contracts and grants from agencies such as the Department of Health and Human Services...
This is a $30,704,925.57 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Achaogen, Inc., a for-profit organization. The contract was awarded on September 1, 2008, with a period of performance through August 27, 2016, and was not set aside for any specific business type. The contract was awarded under a Broad Agency Announcement (BAA) solicitation, BAA...
This federal contract award to Microbiotix, Inc., a clinical-stage biopharmaceutical company, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), under a Broad Agency Announcement (BAA). The $14,195,727 cost-plus-fixed-fee contract supports the development of small molecule pan-filovirus entry inhibitors through lead optimization, selection of a preclinical candidate, and IND-enabling preclinical studies. The...
This is a $26,427,820.00 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Revagenix Inc. The contract is for the advanced development of a novel LPXC inhibitor with pan-resistant Pseudomonas and Burkholderia activity. This contract was awarded under a Broad Agency Announcement (BAA) solicitation that sought proposals for research and development of vaccines, therapeutics, and diagnostics...
This is a $3,624,974 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services, to Trius Therapeutics, Inc. for the "DEVELOPMENT OF THERAPEUTIC MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES". The contract has a period of performance from September 16, 2013 to September 15, 2015, with a ceiling value of $845,876.06. There is no set-aside for this award....
This is a cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Vaxine PTY LTD, a for-profit organization located in Australia. The $18,541,473.00 contract is for the "ADVANCED DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES". The contract has an end date of August 14, 2023 and was initially awarded on September 20, 2018. This contract...